To test this prediction, we analyzed the proteases found in both stromal and tumor cells with a focus on the soluble MMP2 and MMP9 proteases and the transmembrane MT1-MMP proteases that are known to drive matrix degradation in many tumor types, including breast, prostate, and pancreatic cancer [11, 37–40]. This evidence concerns the gene MMP9 and neoplasm.